enVVeno Medical Corporation Company profile
About enVVeno Medical Corp
enVVeno Medical Corporation, formerly Hancock Jaffe Laboratories, Inc., is a medical device company. The Company is focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The Company’s lead product, VenoValve, is a surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). It is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial.
Financial summary
BRIEF: For the nine months ended 30 September 2021, enVVeno Medical Corp revenues was not reported. Net loss applicable to common stockholders increased 58% to $7.5M. Higher net loss reflects Research and development expenses increase of 100% to $3.9M (expense), Selling, General & Administrative Expens increase of 33% to $3.9M (expense), FV/Uls Adjust on Derivatives for Hedging decrease from $212K (income) to $0K.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)